206
Participants
Start Date
July 31, 2014
Primary Completion Date
December 31, 2015
Study Completion Date
June 30, 2016
KPI-121
KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Vehicle
The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
South Shore Eye Center, LLP, Wantagh
Virginia Eye Consultants, Norfolk
Abrams Eye Center, Cleveland
Tauber Eye Center, Kansas City
Wolstan & Goldberg Eye Associates, Torrance
Sall Research Medical Center, Artesia
North Valley Eye Medical Group, Mission Hills
UAB School of Optometry, Birmingham
Lead Sponsor
Kala Pharmaceuticals, Inc.
INDUSTRY